Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (PCPA-induced insomnia in mice)
PubMed 39444618 · doi:10.3389/fphar.2024.1439536
What was done
Researchers evaluated the sleep-promoting efficacy and mechanism of a recombinant fusion peptide combining delta sleep-inducing peptide and a blood-brain barrier-crossing peptide (DSIP-CBBBP), expressed in Pichia pastoris. The peptide was tested in a p-chlorophenylalanine (PCPA)-induced insomnia mouse model, comparing DSIP-CBBBP to unfused DSIP. Outcomes included behavioral assessments of sleep and biochemical quantification of neurotransmitters, specifically serotonin (5-HT), glutamate, dopamine (DA), and melatonin.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. It states qualitatively that DSIP-CBBBP modulated levels of 5-HT, glutamate, DA, and melatonin, demonstrating a greater restorative effect on neurotransmitter imbalance and sleep behavior than DSIP without the blood-brain barrier-crossing peptide.
Why it matters
Delivering neuroactive peptides across the blood-brain barrier remains a major hurdle in sleep pharmacology; engineering a yeast-secreted DSIP fusion peptide may enhance central delivery and therapeutic potential.
Limits
This is an animal model study using chemically induced insomnia in mice, which does not fully capture human clinical insomnia. The abstract lacks sample sizes, dosage details, numerical data, and statistical testing results. Human safety, pharmacokinetics, and immunogenicity were not evaluated.
Cited by
- supports DSIP and Epithalon regulate sleep and recovery.